Morepen Labs Clears USFDA Inspection

Abbott Laboratories successfully completed its fourth consecutive USFDA inspection at its Masulakhanna facility in Himachal Pradesh with zero adverse observations (No Form 483 issued). This achievement, which concluded on April 17, 2026, reinforces Abbott Laboratories' commitment to maintaining high global quality and regulatory standards. The company's Chairman and Managing Director, Sushil Suri, and Executive Director and CEO (API), Sanjay Suri, highlighted that this impeccable record strengthens Abbott Laboratories' credibility with global regulators, customers, and partners, paving the way for future long-term supply contracts and engagements of similar scale. This milestone follows a recent multi-year CDMO mandate worth approximately Rs. 825 crore (USD 91 million) from a leading global pharmaceutical major. Abbott Laboratories continues to invest in robust quality management systems, data integrity practices, automation, and digitalization, aligning its operations with evolving global standards like ICH and CFR (Part-21) guidelines. The company exports Active Pharmaceutical Ingredients (APIs) to over 80 countries, including the United States and Europe, and is strategically expanding into the Contract Development and Manufacturing Organisation (CDMO) space.